Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Association between On-Treatment Haemoglobin A1c and All-Cause Mortality in Individuals with Type 2 Diabetes: Importance of Personalized Goals and Type of Anti-Hyperglycaemic Treatment.

Orsi E, Bonora E, Solini A, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Zerbini G, Morano S, Nicolucci A, Penno G, Pugliese G.

J Clin Med. 2020 Jan 17;9(1). pii: E246. doi: 10.3390/jcm9010246.

2.

Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up.

Barale C, Bonomo K, Frascaroli C, Morotti A, Guerrasio A, Cavalot F, Russo I.

Nutr Metab Cardiovasc Dis. 2020 Feb 10;30(2):282-291. doi: 10.1016/j.numecd.2019.09.012. Epub 2019 Sep 17.

PMID:
31653513
3.

Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study.

Fadini GP, Li Volsi P, Devangelio E, Poli M, Cazzetta G, Felace G, Avogaro A; DARWIN-T2D Network.

J Endocrinol Invest. 2020 Mar;43(3):329-336. doi: 10.1007/s40618-019-01110-w. Epub 2019 Sep 12.

PMID:
31515744
4.

Hypercholesterolemia impairs the Glucagon-like peptide 1 action on platelets: Effects of a lipid-lowering treatment with simvastatin.

Barale C, Frascaroli C, Cavalot F, Russo I.

Thromb Res. 2019 Aug;180:74-85. doi: 10.1016/j.thromres.2019.06.010. Epub 2019 Jun 15.

PMID:
31229924
5.

Is resistant hypertension an independent predictor of all-cause mortality in individuals with type 2 diabetes? A prospective cohort study.

Solini A, Penno G, Orsi E, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Lamacchia O, Baroni MG, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group.

BMC Med. 2019 Apr 25;17(1):83. doi: 10.1186/s12916-019-1313-x.

6.

Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.

Fadini GP, Sciannameo V, Franzetti I, Bottigliengo D, D'Angelo P, Vinci C, Berchialla P, Arena S, Buzzetti R, Avogaro A; DARWIN-T2D network.

Diabetes Obes Metab. 2019 Aug;21(8):1886-1894. doi: 10.1111/dom.13747. Epub 2019 May 8.

7.

Simvastatin Effects on Inflammation and Platelet Activation Markers in Hypercholesterolemia.

Barale C, Frascaroli C, Senkeev R, Cavalot F, Russo I.

Biomed Res Int. 2018 Oct 1;2018:6508709. doi: 10.1155/2018/6508709. eCollection 2018.

8.

Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study.

Fadini GP, Solini A, Manca ML, Zatti G, Karamouzis I, Di Benedetto A, Frittitta L, Avogaro A; DARWIN-T2D Network.

Acta Diabetol. 2018 Nov;55(11):1121-1129. doi: 10.1007/s00592-018-1194-z. Epub 2018 Aug 9.

PMID:
30090961
9.

Cardioprotective Properties of Human Platelets Are Lost in Uncontrolled Diabetes Mellitus: A Study in Isolated Rat Hearts.

Russo I, Femminò S, Barale C, Tullio F, Geuna S, Cavalot F, Pagliaro P, Penna C.

Front Physiol. 2018 Jul 10;9:875. doi: 10.3389/fphys.2018.00875. eCollection 2018.

10.

Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study.

Penno G, Solini A, Orsi E, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Lamacchia O, Scardapane M, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group.

Diabetologia. 2018 Nov;61(11):2277-2289. doi: 10.1007/s00125-018-4691-2. Epub 2018 Jul 21.

PMID:
30032426
11.

Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study.

Fadini GP, Bottigliengo D, D'Angelo F, Cavalot F, Bossi AC, Zatti G, Baldi I, Avogaro A; DARWIN-T2D Network.

Diabetes Ther. 2018 Aug;9(4):1477-1490. doi: 10.1007/s13300-018-0452-y. Epub 2018 Jun 1.

12.

Haemoglobin A1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes.

Orsi E, Solini A, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Gruden G, Morano S, Nicolucci A, Penno G, Pugliese G; Renal Insufficiency and Cardiovascular Events (RIACE) Study Group.

Diabetes Obes Metab. 2018 Aug;20(8):1885-1893. doi: 10.1111/dom.13306. Epub 2018 Apr 19.

PMID:
29582548
13.

Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study.

Penno G, Solini A, Bonora E, Orsi E, Fondelli C, Zerbini G, Trevisan R, Vedovato M, Cavalot F, Laviola L, Nicolucci A, Pugliese G; Renal Insufficiency and Cardiovascular Events (RIACE) Study Group.

Acta Diabetol. 2018 Jun;55(6):603-612. doi: 10.1007/s00592-018-1133-z. Epub 2018 Mar 24.

PMID:
29574497
14.

Platelets, diabetes and myocardial ischemia/reperfusion injury.

Russo I, Penna C, Musso T, Popara J, Alloatti G, Cavalot F, Pagliaro P.

Cardiovasc Diabetol. 2017 May 31;16(1):71. doi: 10.1186/s12933-017-0550-6. Review.

15.

Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation.

Barale C, Buracco S, Cavalot F, Frascaroli C, Guerrasio A, Russo I.

Thromb Haemost. 2017 Jun 2;117(6):1115-1128. doi: 10.1160/TH16-07-0586. Epub 2017 Apr 13.

16.

Independent correlates of urinary albumin excretion within the normoalbuminuric range in patients with type 2 diabetes: The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study.

Penno G, Solini A, Zoppini G, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Gruden G, Lamacchia O, Laviola L, Orsi E, Pugliese G; Renal Insufficiency Cardiovascular Events (RIACE) Study Group.

Acta Diabetol. 2015 Oct;52(5):971-81. doi: 10.1007/s00592-015-0789-x. Epub 2015 Jul 10.

PMID:
26155957
17.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group.

N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. Erratum in: N Engl J Med. 2015 Aug 6;373(6):586.

18.

Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies.

Sottero B, Gargiulo S, Russo I, Barale C, Poli G, Cavalot F.

Med Res Rev. 2015 Sep;35(5):968-1031. doi: 10.1002/med.21349. Epub 2015 May 6. Review.

PMID:
25943420
19.

Resistant hypertension in patients with type 2 diabetes: clinical correlates and association with complications.

Solini A, Zoppini G, Orsi E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Lamacchia O, Arosio M, Baroni MG, Penno G, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group.

J Hypertens. 2014 Dec;32(12):2401-10; discussion 2410. doi: 10.1097/HJH.0000000000000350.

PMID:
25198422
20.

Chronic kidney disease in type 2 diabetes: lessons from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study.

Pugliese G, Solini A, Bonora E, Fondelli C, Orsi E, Nicolucci A, Penno G; RIACE Study Group.

Nutr Metab Cardiovasc Dis. 2014 Aug;24(8):815-22. doi: 10.1016/j.numecd.2014.02.013. Epub 2014 Mar 1. Review.

PMID:
24780515

Supplemental Content

Loading ...
Support Center